Trials / Completed
CompletedNCT02249728
Absorption, Metabolism and Excretion Study of [14C]PBT2 and Absolute Bioavailability of PBT2
A Phase I , Open-Label Study to Evaluate the Absorption, Metabolism and Excretion of [14C]-PBT2 and to Estimate the Absolute Bioavailability of PBT2 in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Prana Biotechnology Limited · Industry
- Sex
- Male
- Age
- 30 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to investigate how the test drug, PBT2, is taken up, broken down and removed from the body when given as an oral capsule, a radiolabelled oral suspension and a radiolabelled intravenous injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IV PBT2 microtracer and oral PBT2 single dose | |
| DRUG | oral 14C-PBT2 |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2014-07-01
- Completion
- 2014-07-01
- First posted
- 2014-09-26
- Last updated
- 2016-03-30
- Results posted
- 2016-03-30
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02249728. Inclusion in this directory is not an endorsement.